U.S. Chamber comments on the Centers for Medicare & Medicaid Services' ("CMS's") Draft Guidance implementing Initial Price Applicability Year 2028 ("IPAY 2028") of the Medicare Drug Price Negotiation Program created by the Biden Administration under the Inflation Reduction Act ("IRA").
Recommended
- Intellectual Property
The MFN Trap: Copycat Price Controls Threaten Tomorrow's Cures
MFN pricing undermines innovation, delays treatments, and threatens economic growth.
By Brad Watts
View this online




